$TSEM

Fri: Weak defense stocks weigh on indices

Friday on the Tel Aviv Stock Exchange, major indices declined. Tel Aviv 35 fell 0.33% to 4,202.63 and Tel Aviv 125 fell 0.31% to 4,074.63. Defense and renewable energy sector indices dropped, while chemicals rubber and plastics rose. FX rates weakened versus the dollar and euro. Bank Hapoalim rose 0.31%, Tower Semiconductor fell 4.35%, Teva fell 2.28%.

Original reporting
Published Aug 16, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 16, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Fri: Weak defense stocks weigh on indices — source image
Decision brief

The 30-second read

$TSEMNeutralLow
01

Why it matters

The only explicit fundamental event is Nofar Energy’s announced acquisition of HighLight for NIS 200 million; other listed moves are presented without catalysts.

02

Market read

Traders get a same-day read on TASE risk appetite, with defense and renewables under pressure and one deal-driven single-name catalyst.

03

What to watch

Defense and renewable weakness may reflect macro or hedging flows rather than company fundamentals; without attribution, single-name moves may be non-informational.

Relevance 4/10Novelty 3/10Timing: Friday session market wrap, mid-day timestamp (13:30 UTC)

Background

This is a Tel Aviv market wrap describing index performance, sector moves, FX moves, and a list of notable single-stock gainers and losers.

Company-level read

Ticker impact

$TSEMNeutralLow confidence
Context

Tower Semiconductor dropped 4.35% on Friday, listed as a notable decliner in the article.

Expected impact

Short-term volatility possible, but directionally unconfirmed by fundamentals here.

Evidence & confidence

The article lacks a catalyst; it is a market wrap with price moves only.

$TEVANeutralLow confidence
Context

Teva fell 2.28% on Friday, included in the article’s notable decliners list.

Expected impact

No high-conviction trade signal from this article alone.

Evidence & confidence

Only the daily move is provided; no earnings, trial, or guidance update appears.

$NICENeutralLow confidence
Context

Nice rose 6.48% on Friday, called out as a notable advancer in the article.

Expected impact

Potential momentum, but catalyst risk remains high without further detail.

Evidence & confidence

The article reports the move magnitude without explaining what drove it.

$GILTNeutralLow confidence
Context

Gilat Satellite Systems fell 4.43% on Friday, listed among notable decliners.

Expected impact

Limited actionable signal without a stated catalyst.

Evidence & confidence

No event, filing, or guidance change is described for Gilat.

Market effects

Defense and renewable energy sector indices fell 1.62% and 1.49%, suggesting risk-off rotation within TASE sectors.

Broader Tel Aviv index weakness alongside shekel depreciation (USD -0.97%, EUR -0.83%) may pressure risk assets.

Limited direct global linkage; mainly a regional tape and sector rotation snapshot.

Counterpoint

The article’s biggest single-company catalyst is an acquisition, but the stock drop could be an overreaction that reverses if deal terms are later clarified.

Key entities

  • Tel Aviv 35 Index

    Fell 0.33% to 4,202.63 points on Friday.

  • Tel Aviv Defense Index

    Dropped 1.62% on Friday.

  • Nofar Energy

    Fell 5.42% after announcing acquisition of HighLight for NIS 200 million.

  • HighLight

    Solar energy and storage company being acquired by Nofar Energy.

Related articles

$ALCLow

Here's How Trump's Drug Deals Are Likely to Impact Healthcare ETFs

President Trump expanded drug-pricing agreements with 9 international companies, including Alcon and Teva, adding to 17 prior deals with firms like Pfizer. The MFN framework now covers 89% of the branded drug market. The impact on healthcare ETFs is mixed, with potential benefits for insurers (IHF) and uncertain effects on U.S. pharma (PPH).

$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

$TSEMHigh

Tower Semiconductor TSEM Draws Bullish Targets On AI Photonics

Tower Semiconductor (TSEM) shares rose 7.85% after announcing a capacity expansion and new partnerships. The company's stock closed at $222.34, below the Street's consensus target of $314.88. BofA Securities initiated coverage with a Buy rating and a $367 target, citing growth in silicon photonics for AI data centers. TSEM's revenue is expected to double in 2026, driving trader interest.

$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.